Brief: Nymox says new phase 3 long-term U.S.results for fexapotide show major decrease in prostate cancer

Nymox Pharmaceutical

29/08/2016 15:55

Aug 29 (Reuters) - Nymox Pharmaceutical Corp  NYMX.O  :  
    * Nymox's new Phase 3 long-term U.S. results for prostate 
enlargement drug fexapotide show decrease in prostate cancer  
    * Fexapotide has been found to show clinically meaningful 
and durable relief of BPH symptoms 
    * Fexapotide  has also been found to show major reduction in 
incidence of prostate cancer versus placebo 
    * Expects to file for approvals in next 1-2 quarters 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nGNXNABDZa 
Further company coverage:  NYMX.O  
 
 ((Bangalore.newsroom@thomsonreuters.com ;))